1 The EIC Accelerator Project

Overview of the EIC Accelerator Program

The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support small and medium-sized enterprises (SMEs) and startups in the European Union that are developing innovative technologies and solutions. This initiative aims to foster growth in the DeepTech ecosystem by providing substantial funding and resources to help companies scale their operations and bring groundbreaking products to market.

The EIC Accelerator offers a blended financing model that combines grants and equity investments. Eligible companies can receive grants of up to €2.5 million to cover project costs, while equity funding can reach up to €15 million until 2024 and €10 million from 2025 onwards. This flexible funding structure is tailored to the specific needs of each project, enabling companies to choose the right mix of financial support to achieve their goals.

Purpose of the EIC Accelerator

The primary purpose of the EIC Accelerator is to bridge the funding gap faced by innovative companies in Europe, particularly in high-risk sectors like DeepTech. By providing significant financial resources, the program enables startups to develop their products and services, thus driving innovation and economic growth. The EIC Accelerator also plays a crucial role in helping companies attract additional funding from private investors, increasing their chances of success in a competitive market.

Through its support, the EIC Accelerator facilitates partnerships and collaboration between companies, research institutions, and investors. This collaborative approach enhances the overall ecosystem, encouraging the exchange of ideas and accelerating the commercialization of innovative solutions.

Antabio SAS and the sbli-ant3310 Project

Company Overview Antabio SAS, based in France, emerged as a winner of the EIC Accelerator for its innovative project, sbli-ant3310. This project focuses on developing a novel combination treatment aimed at combating multidrug-resistant pathogens identified as a critical priority by the World Health Organization (WHO).

Project Description: sbli-ant3310 The sbli-ant3310 project addresses a pressing global health issue: the rise of multidrug-resistant infections. These pathogens pose significant threats to public health, leading to increased morbidity, mortality, and healthcare costs. Antabio's approach combines existing antibiotics with a newly developed compound, creating a synergistic effect that enhances the efficacy against resistant strains.

Technology Basics and Background

Antabio's technology is rooted in the understanding of bacterial resistance mechanisms and the pharmacodynamics of existing antibiotics. The novel compound within the sbli-ant3310 treatment works by inhibiting specific bacterial pathways that confer resistance, thereby restoring the effectiveness of traditional antibiotics. This dual-action mechanism not only targets the bacteria more effectively but also minimizes the likelihood of developing further resistance.

The project has undergone rigorous preclinical testing, demonstrating promising results in vitro and in animal models. These studies have shown that the combination treatment can effectively reduce bacterial load and improve survival rates in infected hosts. The successful development of sbli-ant3310 represents a significant advancement in the fight against antibiotic resistance, aligning with global health initiatives aimed at preserving the efficacy of existing antibiotics.

Conclusion

The EIC Accelerator program plays a vital role in supporting innovative companies like Antabio SAS in their mission to tackle critical health challenges. By providing substantial financial resources and facilitating connections with private investors, the program enhances the potential for groundbreaking solutions to emerge in the European DeepTech ecosystem. The sbli-ant3310 project exemplifies this effort, targeting one of the most pressing issues in modern medicine and offering a promising pathway to combat multidrug-resistant infections effectively. For more information, Antabio can be visited at antabio.com.

2 The Funding Rounds

Antabio SAS: Financing and Funding Events Since EIC Accelerator Success (June 2022)

Overview

Antabio SAS, based in France, is a clinical-stage biopharmaceutical company specializing in novel treatments for severe drug-resistant bacterial infections. The company was selected as an EIC Accelerator winner following the June 2022 cut-off, receiving blended finance support to advance its lead program targeting multidrug-resistant pathogens.

---

Major Funding Rounds and Amounts

• Series B Financing (December 2023)
• Amount Raised: €25 million (approximately $26.98 million)
• Date Closed: December 12–13, 2023
• Lead Investors: AMR Action Fund and the European Innovation Council (EIC) Fund
• Other Investors: BNP Paribas Développement, Relyens Innovation Santé / Turenne Capital, IRDI Capital Investissement, Christophe Ricard (former President of OM Pharma)
• Purpose: To support the clinical development of MEM-ANT3310 through completion of Phase II trials.
• EIC Accelerator Blended Finance Award (June/July 2022)
• Antabio received blended financing from the European Innovation Council as part of its June 15, 2022 accelerator cohort. Public records indicate this included a grant component (€2.5 million) awarded in June 2022 and an equity component (€3 million) from the EIC Fund in June/July/August of subsequent years.
• This financing contributed to launching ARPEGE—a multidisciplinary antimicrobial resistance consortium—backed by €5.5 million public funding for MEM-ANT3310’s advancement toward clinical studies.

---

Funding Timeline

Date	Round/Funding Type	Amount	Lead/Key Investors
Dec. 12–13, 2023	Series B	€25M ($26.98M)	AMR Action Fund; EIC Fund; historical investors
Jun.–Jul., 2022	EIC Accelerator blended finance/grant	~€2.5M–€3M	European Innovation Council
Dec., 2018	Series A	€12.5M	Omnes; BNP Paribas Développement; Sham Innovation Santé/Turenne Capital; iXO Private Equity; IRDI SORIDEC Gestion; Galia Gestion

Note: Earlier rounds prior to mid-2022 are outside this scope but include significant grant financing from Wellcome Trust and CARB-X.

---

Investor Information

Key participants since June 2022:

• AMR Action Fund
• European Innovation Council (EIC) Fund
• BNP Paribas Développement
• Relyens Innovation Santé / Turenne Capital
• IRDI Capital Investissement
• Christophe Ricard

The continued participation from both new investors like AMR Action Fund and existing backers underscores confidence in Antabio’s strategy and scientific pipeline.

---

Company Valuation

No explicit post-money valuation has been publicly disclosed for Antabio’s Series B round or other funding events since mid‑2022 across available sources.

---

Exit Events: IPOs or Acquisitions

As of May 6th (UTC), Antabio remains privately held with no reported IPO filings or buyout/acquisition announcements since their EIC Accelerator award. All recent activities have focused on fundraising to support advanced-stage clinical programs rather than exit strategies.

---

Summary Table: Key Post-EIC Funding Events

Date	Event	Amount
Jun.–Jul., 22	EIC Blended Finance Grant	~€2.5–€3 Million
Dec., 23	Series B	€25 Million

No exits have occurred up to early May 2025.

---

Sources

EIC Accelerator winners and statistics June 2022 – Strata.team Selected companies – EIC Accelerator cut-off list PDF Antabio company information – Texas Dealroom Antabio funding & investors – Alternative Protein Dealroom History & key facts – Antabio official site ANTABIO Raises €25 million in Series B Financing – BEAM Alliance ANTABIO raises $26,976,000 at Series B on Founder Lodge Antabio completes €12.5m Series A — Antabio News Archive

3 The Press Releases

Antabio SAS: Post-EIC Accelerator Funding Overview Antabio SAS, a French clinical-stage biopharmaceutical company, secured EIC Accelerator funding in June 2022 through its proposal for a novel combination therapy targeting multidrug-resistant pathogens classified as critical priorities by the WHO. The company specializes in developing antibacterial solutions to address antimicrobial resistance (AMR), with its EIC-funded project focusing on blended finance support.

Key Details

• EIC Funding: Awarded under the June 15, 2022, cut-off as part of the €400 million funding pool for 75 companies. Antabio’s selection highlights its focus on combating high-priority pathogens like Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae.
• Technology: The funded project aims to advance a combination therapy designed to overcome resistance mechanisms in critical Gram-negative bacteria, though specifics about preclinical/clinical stages remain undisclosed in publicly available materials.
• Collaborations & Patents: No recent press releases or blog posts from antabio.com were identified via the provided sources. Patent activity would require Espacenet searches beyond the scope of current data.

Gaps Identified:

• No direct social media updates or press releases from antabio.com detailing post-funding milestones (e.g., trials, partnerships).
• Limited public updates about team expansions or technology advancements since June 2022.

---

Sources

• EIC Accelerator winners and statistics June 2022 - Strata.team
• Selected companies - EIC Accelerator 15 June cut-off (PDF)
• Espacenet - patent search | epo.org

4 The Technology Advancements

Overview of Antabio SAS

Antabio SAS is a French biopharmaceutical company based in Labège, France, and founded in 2009. The company specializes in developing antibacterial resistance-breakers for treating drug-resistant infections, prioritized by the World Health Organization. Antabio's focus on combating antimicrobial resistance aligns with global health priorities, as this issue is projected to cause significant mortality by 2050.

Advancements Since EIC Accelerator Funding

In June 2022, Antabio SAS became an EIC Accelerator winner, but specific details about the impact of this funding on their advancements are not readily available. However, the company has made significant strides in its research and development activities since then.

Recent Developments

• Series B Financing: In December 2023, Antabio raised €25 million in a Series B financing round, led by the AMR Action Fund, with support from the European Innovation Council (EIC) Fund and historical investors. This funding is dedicated to supporting the clinical development of MEM-ANT3310, a next-generation antibacterial combination targeting severe drug-resistant Gram-negative pathogens.
• MEM-ANT3310 Clinical Trials: The company began Phase 1 clinical trials for MEM-ANT3310 in 2023, with plans to complete Phase 2 trials using the Series B funding. This compound combines meropenem with ANT3310, a serine-beta-lactamase inhibitor, offering a novel solution for infections caused by carbapenem-resistant bacteria.
• EMA PRIME Designation: Recently, MEM-ANT3310 secured the EMA PRIME designation for addressing antimicrobial resistance in severe hospital infections.

Technology and Market Demonstration

While Antabio has not specifically detailed new technological features since the EIC funding, their focus remains on developing innovative antibacterial combinations like MEM-ANT3310. The clinical trials for this compound serve as a demonstration of their technology in addressing critical medical needs.

Patents, Scientific Studies, and Clinical Trials

There is no specific information available about new patents filed or scientific studies published directly following the EIC Accelerator funding. However, the company's ongoing clinical trials, such as those for MEM-ANT3310, contribute to advancing the scientific understanding and treatment of drug-resistant infections.

Conclusion

Antabio SAS continues to advance in the field of antibacterial resistance-breakers, driven by significant funding and strategic partnerships. Their focus on developing novel treatments for drug-resistant infections positions them as a key player in addressing the global antimicrobial resistance crisis.

Sources:

• Antabio
• Antabio S.A.S. - BioCentury Company Profiles
• AMR-Targeting Drug Secures EMA PRIME Designation
• ANTABIO Raises €25 Million in Series B Financing
• ANTABIO Awarded Up to $8.9M from CARB-X
• ANTABIO Raises €25 Million in Series B Financing
• Antabio SAS - Partnering @JPM Week 2025
• History and Key Facts - Antabio
• Pipeline - Antabio

5 The Partnerships and Customers

Overview of Antabio SAS

Antabio SAS, a French biopharmaceutical company, has been actively developing novel antibacterial treatments to combat drug-resistant infections. Since receiving EIC Accelerator funding in June 2022, Antabio has made significant strides in partnerships, technology advancements, and market positioning.

Partnerships and Customers

• AMR Action Fund: Antabio SAS has partnered with the AMR Action Fund, a critical investor in its Series B financing round. The AMR Action Fund is dedicated to addressing antimicrobial resistance, a global health crisis.
• EIC Fund: Another key partner is the EIC Fund, which has supported Antabio through significant investments, recognizing its innovative pipeline and European innovation.
• Existing Investors: Antabio has maintained strong relationships with its existing investors, who have shown continued support through additional funding rounds.
• CARB-X: Antabio has received funding from CARB-X, a non-profit partnership focused on accelerating antibacterial R&D, particularly for treating Pseudomonas aeruginosa infections in cystic fibrosis patients.

New Partners

As of recent developments, Antabio has welcomed the AMR Action Fund and the EIC Fund as new partners during its Series B financing. These partnerships underscore Antabio's growing influence in addressing antimicrobial resistance globally.

New Customers

Information on specific new customers is not available, but Antabio's focus on treating critical priority pathogens positions the company to serve a global market in need of effective antibacterial treatments.

Nature of New Relationships and Purpose

The new partnerships, particularly with the AMR Action Fund and the EIC Fund, are aimed at advancing Antabio's pipeline of antibacterial drugs. These relationships are crucial for supporting the clinical development of novel treatments like MEM-ANT3310, which targets drug-resistant Gram-negative pathogens.

Positioning in the Market

Antabio's partnerships and funding position it as a leader in the fight against antimicrobial resistance. The company's innovative pipeline, including treatments for life-threatening infections such as Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP), aligns with global health priorities.

Technology Advancements and Scaling

These partnerships will significantly aid Antabio in technology advancements by providing the financial resources needed to progress its clinical trials. For instance, the Series B funding will support the completion of Phase 2 studies for MEM-ANT3310, a critical step towards market approval. Additionally, the collaborations enhance Antabio's ability to scale its operations, ensuring its treatments reach a broader audience and contribute meaningfully to addressing the AMR crisis.

Sources:

• Antabio SAS raises €25 m in Series B financing
• News - Antabio
• Antabio
• Antabio company information, funding & investors
• ANTABIO Raises €25 Million in Series B Financing
• Antabio SAS - BIO CEO & Investor Conference
• Antabio SAS advances cystic fibrosis programme
• ANTABIO Announces Key Executive Appointments

6 The Hiring and Company Growth

Antabio SAS: Team Growth and Scaling Post-EIC Accelerator Funding

Antabio SAS, a French biotech company focused on addressing antibiotic resistance, secured EIC Accelerator funding in June 2022. While specific hiring figures or current headcount are not publicly detailed in available sources, the company is listed among key players in the competitive antibiotic resistance therapeutics market. This sector is experiencing significant growth due to rising global demand for novel antimicrobial solutions, driven by increasing drug-resistant infections and government incentives for innovation.

Team Growth and Hiring Trends
Though Antabio’s exact team size remains undisclosed, EIC Accelerator funding typically enables awardees to scale operations, suggesting potential recruitment in critical roles such as R&D scientists, clinical trial managers, and regulatory affairs specialists. Companies in this field often prioritize hires with expertise in microbiology, drug development pipelines, and partnerships with academic institutions or larger pharmaceutical firms.

Strategic Impact of New Hires
Expanding teams would allow Antabio to accelerate preclinical/clinical programs highlighted during its EIC application phase. Key positions likely include:

• Antimicrobial resistance (AMR) researchers: To advance novel compounds targeting priority pathogens like MRSA or Clostridioides difficile.
• Business development leads: To secure partnerships for late-stage trials or commercialization.
• Regulatory experts: To navigate evolving guidelines for antibiotic approvals.

Growth aligns with broader industry trends where smaller biotechs leverage non-dilutive funding (e.g., EIC grants) to de-risk projects before engaging Big Pharma collaborators. No major management changes have been reported post-funding.

---

Sources

• Antibiotic Resistance Markets Therapeutics Report 2024
• Antibiotic Resistance Therapeutics Market Research Report 2025–2029

7 The Media Features and Publications

Overview of Antabio SAS

Antabio SAS, a French biopharmaceutical company, was recognized as an EIC Accelerator winner in June 2022. The company is dedicated to developing novel antibacterial treatments, focusing on drug-resistant infections deemed critical by the World Health Organization (WHO).

Media Features and Publications

While specific media features directly mentioning Antabio SAS post-EIC funding in 2022 are not detailed in the available search results, publications typically highlight the company's role in combating drug-resistant infections. For example, Antabio's work on metallo β-lactamase inhibitors like ANT2681 has been noted in scientific contexts, such as presentations at the ASM Microbe Conference.

Podcasts and Interviews

In January 2022, Antabio's CEO Marc Lemonnier participated in a podcast discussing the global issue of antimicrobial resistance (AMR) and the clinical landscape of innovative antibiotic therapies.

Conferences and Presentations

Antabio has been active in presenting its research, notably at the ASM Microbe Conference in 2019. During this event, the company presented data on its novel metallo β-lactamase inhibitor, ANT2681, highlighting its potential to restore the efficacy of meropenem against NDM-producing carbapenem-resistant Enterobacteriaceae (CRE).

Involvement in Events

While specific details on recent event participations post-EIC funding are limited, Antabio's involvement in scientific conferences underscores its commitment to advancing antibacterial research and development.

Conclusion

Antabio SAS continues to make significant strides in addressing drug-resistant infections through innovative treatments and active participation in scientific forums.

Sources

• Antabio (https://antabio.com)
• Antabio S.A.S. (https://profiles.biocentury.com/companies/antabio_sas)
• Antabio company information (https://startupportugal.dealroom.co/companies/antabio)
• Antabio company information (https://ecosystem.brnoregion.com/companies/antabio)
• Antabio completes €12.5m Series A (https://www.omnescapital.com/press-release/antabio-completes-e12-5m-series-a)
• Podcast - Antabio (https://antabio.com/podcast/)
• Antabio's Novel Metallo β-Lactamase Inhibitor (https://antabio.com/2019/06/04/antabios-novel-metallo-%CE%B2-lactamase-inhibitor-to-be-presented-at-the-asm-microbe-conference-june-20-24-san-francisco)
• bioMérieux Universal Registration Document (https://www.biomerieux.com/content/dam/biomerieux-com/investor/02---news---reports/urd-fr/bioMerieux-URD-2021-EN.pdf.coredownload.pdf)
• Press Release - Antabio (https://antabio.com/wp-content/uploads/2018/01/PR_Antabio_Series-A_ENG_VF_immediate-release.pdf)